We report a case involving unusually high postmortem morphine concentrations in a 44-year-old male with end-stage pancreatic cancer. He was receiving morphine for pain control via a single subclavian intravenous catheter. Allegations of foul play were made by family members at the time of death, so a full autopsy was performed. Comprehensive toxicology on autopsy samples indicated that morphine was the only drug present. Quantitative analysis of free and total morphine revealed extraordinarily high concentrations of the drug. Free morphine concentrations in heart blood, vitreous fluid, brain, liver, stomach contents, and urine were 96 mg/L, 52 mg/L, 26 mg/kg, 88 mg/kg, 82 rag/L, and 976 rag/L, respectively. Total morphine concentrations in heart blood, vitreous fluid, brain, liver, and stomach contents were 421 mg/L, 238 rag/L, 65 mg/kg, 256 mg/kg, and 325 rag/L, respectively. Records indicate that the infusion pump may have continued to deliver the drug for 15-45 rain following death. Despite compelling toxicological data, the cause of death was determined to be complication of adenocarcinoma of the pancreas, and the manner was natural. This report highlights issues surrounding postmortem toxicological interpretation within the context of chronic pain management.
Introduction
Morphine is widely utilized for the treatment of moderate to severe pain and sets the standard by which all other analgesics are measured. It can be administered orally or by subcutaneous, intramuscular, intravenous, epidural, or intrathecal injection. Initial doses of 10 rag/70 kg are commonly administered because large doses to non-tolerant individuals may result in severe respiratory depression. Doses greater than 30 mg parenterally or 100 mg orally in a non-tolerant adult may result in adverse or toxic reactions including pupillary constriction, nausea, vomiting, hypothermia, drowsiness, respiratory depression, hypotension, coma, and death. Morphine has a half-life of 1.3-6.7 h and a volume of distribution of 2-5 L/kg (1) . Free morphine in urine accounts for approximately 10% of the dose (1) . The majority of morphine is inactivated via conjugation to morphine-3-glucuronide, with subsequent elimination via the bile, where it undergoes extensive enterohepatic recirculation. Despite its pharmacological activity, morphine-6-glucuronide is a minor metabolite. However, dose, route of administration, gender, age, and renal function are all reported to influence concentrations of morphine and its glucuronidated conjugates during chronic treatment of cancer pain.
In a series of 10 morphine fatalities where no other drugs were detected, total morphine concentrations were measured in the range 0.2 to 2.3 mg/L (mean 0.7 rag/L) (2) . In a larger series of 87 medical examiner cases, free and total morphine concentrations averaged 0.5 and 2.3 rag/L, respectively (3) . Although the percentage of free morphine averaged 19.4% for all cases, higher percentages of free morphine were detected in heroin users whose blood contained detectable levels of 6-monoacetylmorphine. The ratio of free to total morphine can be a useful indicator of survival interval (4) . High percentages of free morphine are associated with rapid deaths, compared with lower percentages of free morphine where survival time may be on the order of several hours. Nevertheless, interpretation of postmortem toxicology is complicated by the fact that therapeutic, toxic, and fatal concentrations overlap because of variability in tolerance. Dosing regimens for palliative care and pain relief can be orders of magnitude higher than those required for acute pain relief in naive subjects. In one study, daily oral morphine doses of 10-2540 mg were reported in cancer patients, resulting in free and total morphine concentrations in the ranges of < 0.001-1 mg/L and 0.02-30 rag/L, respectively (5) .
Furthermore, comprehensive toxicology testing is not commonly performed for persons who have undergone palliative care. As a result, there are limited reference ranges for free and total morphine concentrations in these types of forensic cases. Antemortem data in chronic pain patients is also limited. A recent report suggested that therapeutic drug monitoring as a routine tool during chronic morphine treatment has limited value in terms of clinical decision making because of poor correlation between drug concentration and effect (6) .
Case History
A 44-year-old male, diagnosed the previous year with pancreatic cancer, died at home while receiving pain management using a morphine pump. Because of progressive pain and complications relating to the cancer, the subject required increasing doses of morphine to relieve his discomfort. Morphine was delivered via an intravenous catheter initiated in the subclavian vein and terminated in the superior vena cava. The decedent was reported to be resting comfortably on the day of his death. A short time later, he began to have respiratory difficulty, and he became unresponsive. His wife contacted the hospice nurse, who arrived to find the decedent without signs of life approximately 15-45 min later. The morphine pump continued to run and supply medication to the decedent during this time period. Neither the rate of drug delivery, nor the volume of drug that remained in the pump after death was known. Under ordinary circumstances a full autopsy would not have been performed. However, family members and friends of the decedent advised the authorities of their suspicion that the wife may have poisoned her husband. The decedent was pronounced dead at 0753 a.m., and an autopsy was performed approximately 48 h later.
Experimental
Routine toxicology testing consisted of blood alcohol analysis by gas chromatography-flame ionization detection followed by enzyme-linked immunosorbent assays (ELISA) for opiates, methamphetamine, benzodiazepines, cocaine metabolite, barbiturates, methadone, and propoxyphene (Orasure Technologies). Postmortem tissues were homogenized with saline solution prior to analysis. Quantitative free morphine analysis was conducted using solid-phase extraction (SPE) and gas chromatography-mass spectrometry (GC-MS) as follows. Deuterated internal standard (morphine-d:~, Cerilliant) was added to 1 mL of sample to give a final concentration of 0.25 mg/L. Proteins in blood and tissue were precipitated by addition of cold acetonitrile (2 mL) while vortex mixing, followed by centrifugation at 4000 rpm for 10 rain. The supernatant was transferred to a clean tube, and 1 mL of 0.1M HCI was added. Acidified samples were added to Cerex Clin II SPE columns (SPEWare) and allowed to flow under gravity. Columns were then washed with 1-mL aliquots of deionized water, 0.1M HCI, methanol, and ethyl acetate in that order. Columns were then dried under vacuum for 5 rain. Morphine was eluted from the column using 1 mL methylene chloride/isopropyl alcohol (80:20) containing 2% concentrated ammonium hydroxide. Extracts were evaporated to dryness under nitrogen. Samples were reconstituted using 15 IJL ethyl acetate and 15 IlL N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) followed by derivatization at 70~ for 15 rain. For total morphine determination, deuterated morphine-3-glucuronide was used as the internal standard. Following addition of 0.25 mg/L morphine-3-glucuronide-d3 (Cerilliant), samples were incubated for 3 h at 37~ with 5000 units of E. coli Type IX ]3-glucuronidase (Sigma). After deconjugation and cooling to room temperature, samples were assayed as described.
An HP 5973 MSD with 30-m DB-5 column (0.25-ram i.d., 25-lain film thickness) was used for separation and identification. A 2-1JL splitless injection was delivered onto the column, which was temperature programmed as follows: initial temperature 160~ with a ramp of 30~ to 260~ (held 2 rain), then 30~ to 290~ (held 5 rain). The injector and interface temperatures were 250 and 280~ respectively. Data were acquired by selective ion monitoring (rn/z 429,324, 287 for morphine and 432, 327, and 291 for morphine-d3). Quantitation ions are shown in bold. Calibration curves were constructed between 0.010 and 1.000 mg/L by fortification of bovine blood with the appropriate drug standard. R 2 values in the linear range were 0.999 or greater. The limits of detection and quantitation were 0.005 and 0.010 mg/L. These were defined as the lowest concentration of drug that produced a signal-to-noise ratio of 3:1 or 10:1 respectively, and with ion ratios with acceptable limits (_+ 20%). Accuracy was 93-97% using in-house controls fortified with free morphine between 0.015 and 0.950 rag/L, and 89-104% for total morphine in the range 0.067-0.417 mg/L. Replicate analysis of a commercial whole blood control (Utak Laboratories)indicated 104% accuracy and an intra-assay CV of 6.6% (n = 4). A commercial free morphine whole blood control was included with each run in addition to in-house controls for both free and total morphine. 
Results and Discussion
Preliminary drug screen results were positive for opiates. No other drugs or alcohol were indicated. Quantitative analysis of the heart blood indicated a free morphine concentration in excess of 5 mg/L by GC-MS. Because of the unusually high concentration of free drug, additional autopsy specimens were retrieved for further analysis. Following appropriate dilution of the specimens, morphine concentrations in heart blood, vitreous fluid, liver, brain, urine, and stomach contents were quantitatively determined, and these are depicted in Table I .
Our laboratory does not routinely perform total morphine concentrations on every sample. However, free morphine concentrations in this case were very much higher than in previously analyzed casework. In a series of 176 consecutive femoral blood morphine determinations in our laboratory, the range of free morphine was 0.02-1.64 rag/L, and the mean and median concentrations were 0.17 and 0.11 mg/L, respectively. Free and total morphine concentrations were measured in a series of 44 consecutive morphine-related medical examiner cases from our laboratory. Free and total morphine concentrations ranged from 0 to 0.72 and 0.13 to 6.85 rag/L, respectively. Mean and median concentrations of free morphine were 0.17 and 0.13 mg/L compared with 0.85 and 0.54 mg/L for mean and median concentrations of total morphine. The percent free morphine ranged from 0 to 50% with mean and median values of 26% and 27%, respectively.
Quantitative analysis in this case revealed concentrations of morphine that were the highest ever reported in our laboratory. Furthermore, we are not aware of other published case reports involving morphine concentrations of this magnitude in the scientific literature to date. In another case report, an 83-year-old woman had respective free and total blood morphine concentrations of 5.2 and 15 mg/L following palliative pain therapy (7) . The cause of death was morphine intoxication, but this was later challenged and overturned by an administrative law court following testimony from palliative care experts who argued that because of physiological tolerance, the drug concentrations were not meaningful.
Published data in patients suffering from chronic pain indicate free morphine concentrations of the order of 0.1 rag/L, although concentrations as high as I mg/L have been reported. Morphine-3-glucuronide concentrations far exceed free morphine concentrations in these studies, typically by 10-to 50-fold because of the longer half life of morphine-3-glucuronide (5, (7) (8) (9) (10) (11) (12) (13) .
Furthermore, the use of a continuous infusion pump may complicate interpretation because of tampering or continued drug delivery postmortem. In an earlier report, a 36-year-old female with a history of back pain was believed to be withdrawing morphine from the reservoir of the pump. Postmortem free and total morphine concentrations of 0.460 and 0.624 mg/L in blood and 0.034 and 0.080 mg/L in vitreous fluid were reported in addition to other drugs (14) .
In this case report, the percentage of free morphine is moderately consistent between tissues and fluids, which may suggest equilibration throughout the body. However, the percentage of free morphine is higher than typically reported in tolerant patients receiving long-term palliative care. Furthermore, based upon the distribution of free and total drug throughout the body, results do not suggest that the elevated morphine concentrations are due to postmortem drug delivery. This would elevate free morphine in the localized compartments, in particular the heart blood, because of its proximity to the point of drug delivery (superior vena cava). Concentrations of morphine in brain are typically low because of poor penetration of the blood-brain barrier. However, the concentration of morphine in the liver relative to the blood is perhaps lower than expected based upon previously published data (2) . In a series of 10 fatal morphine overdoses, total morphine concentrations in blood and liver were 0.2 to 2.3 mg/L and 0.4 to 18 mg/kg, respectively, while urine concentrations were 14 to 81 mg/L. Concentrations of total morphine in liver tissue typically exceed concentrations found in blood, by as much as fivefold (2) . However, in this case study, both free and total morphine concentrations were lower in the blood compared to the liver. Urinary morphine concentrations following overdose were found to exceed concentrations in blood by 6-to 200-fold (2) . In this case report a 10-fold differential between free morphine concentrations in urine and heart blood was observed.
This case report outlines some of the confounding factors surrounding interpretation of postmortem morphine concentrations, where therapeutic, toxic, and fatal ranges may overlap. The authors are unaware of other studies that have measured free or total morphine concentrations of this magnitude in living or deceased persons. For this reason, we find the quantitative morphine data in this case extremely compelling from a toxicological standpoint. However, a number of forensic issues concerning palliative care have yet to be resolved among toxicologists, pathologists, and pain management experts.
